TY - JOUR
T1 - Review new concepts in pharmacotherapy for peripheral arterial disease
AU - Kotalczyk, Agnieszka
AU - Vallabhaneni, Srinivasa Rao
AU - Lip, Gregory Y H
N1 - Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2021/11
Y1 - 2021/11
N2 - PURPOSE OF REVIEW: To provide an overview of new concepts in the pharmacotherapy of patients with peripheral artery disease (PAD).RECENT FINDINGS: Modern therapeutic strategies for patients with PAD include specific symptom management and multidisciplinary prevention of cardiovascular events. Low-dose rivaroxaban in combination with aspirin improves outcomes compared with aspirin monotherapy among patients with PAD. Other novel concepts include the use of bosentan, vorapaxar or sildenafil among symptomatic patients with PAD. Likewise, lipid-lowering therapy reduces the risk of major cardiovascular and limb events.SUMMARY: Personalized management, identification of risk factors and shared-decision making are crucial in improving the best medical therapy for patients with PAD. Further studies are needed to assess the long-term safety and efficacy of novel strategies in real-world patients.
AB - PURPOSE OF REVIEW: To provide an overview of new concepts in the pharmacotherapy of patients with peripheral artery disease (PAD).RECENT FINDINGS: Modern therapeutic strategies for patients with PAD include specific symptom management and multidisciplinary prevention of cardiovascular events. Low-dose rivaroxaban in combination with aspirin improves outcomes compared with aspirin monotherapy among patients with PAD. Other novel concepts include the use of bosentan, vorapaxar or sildenafil among symptomatic patients with PAD. Likewise, lipid-lowering therapy reduces the risk of major cardiovascular and limb events.SUMMARY: Personalized management, identification of risk factors and shared-decision making are crucial in improving the best medical therapy for patients with PAD. Further studies are needed to assess the long-term safety and efficacy of novel strategies in real-world patients.
KW - Aspirin/therapeutic use
KW - Drug Therapy, Combination
KW - Humans
KW - Peripheral Arterial Disease/drug therapy
KW - Platelet Aggregation Inhibitors/therapeutic use
KW - Rivaroxaban/therapeutic use
UR - http://www.scopus.com/inward/record.url?scp=85117993821&partnerID=8YFLogxK
U2 - 10.1097/HCO.0000000000000883
DO - 10.1097/HCO.0000000000000883
M3 - Review article
C2 - 34620790
SN - 0268-4705
VL - 36
SP - 720
EP - 726
JO - Current Opinion in Cardiology
JF - Current Opinion in Cardiology
IS - 6
ER -